Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis (TREXO)

University Hospital, Strasbourg, France

Status: Terminated

Conditions: Toxoplasmosis Infection; Genotype II; Ocular Toxoplasmosis With Recurrences

Treatments: Biological: seropositive for Toxoplasma gondii

Study type: Interventional

Funder types: Other

Identifiers

NCT02863588

6433

Details and patient eligibility

About

Ocular toxoplasmosis (OT) is a major cause of visual impairment worldwide. OT is responsible for 30 to 50% of posterior uveitis. It is characterized by dormant infections that may reactivate without known reasons, causing severe irreversible visual loss. The overall recurrence rate of OT in Europe is greater than 80% for patients and may range from one episode to 11 episodes (1% of OT) in the most extreme cases. Current treatments do not reduce the risk of recurrences and the risk of toxoplasmosis recurrence cannot be predicted in these immunocompetent patients. These clinical and biological expression changes might be related to an individual genetic susceptibility of each patient. The advanced analysis of the entire genome now possible to consider the project.

Enrollment: 16 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• seropositive for Toxoplasma gondii (for patient and parents)
• Infection with genotype II (for patient and parents)
• ocular toxoplasmosis recurrences >5 (patients only)

Exclusion criteria

• Parents seronegative for T. gondii infection
• Infection with others genotypes than type II

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

seropositive for Toxoplasma gondii

Experimental group

Treatment:

Biological: seropositive for Toxoplasma gondii